Skip to search formSkip to main contentSkip to account menu

lenalidomide 25 MG Oral Capsule [Revlimid]

Known as: Revlimid 25 MG Oral Capsule 
National Institutes of Health

Related topics

Related topics

7 relations
Croscarmellose SodiumMagnesium stearateOral CapsuleRevlimid

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Treatment with lenalidomide (Revlimid®), cyclophosphamide (Endoxan®) and prednisone (REP) in relapsed/refractory multiple myeloma patients: results of a single centre retrospective study
Abstract Lenalidomide (Revlimid®) combined with intermittent dexamethasone (the RD regimen) is one of the current standards for… 
2014
2014
Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report
IntroductionHypercalcemia is one of the most common metabolic abnormalities encountered in any form of malignancy. Hypocalcemia… 
2009
2009
T cells helping GVHD: take-away lessons.
Using double cytokine knockout donor CD4 cells, in this issue of Blood , Yi and colleagues help clarify the complex role of IFN… 
2008
2008
Phase II Trial of Lenalidomide (Revlimid™) with Cyclophosphamide and Dexamethasone (RCd) for Newly Diagnosed Myeloma
Background: The combination of lenalidomide and dexamethasone (RD) has been shown to be highly effective as initial therapy for… 
2007
2007
Preliminary Results from a Phase I Study of Revlimid® (Lenalidomide) in Combination with Vidaza® (Azacitidine) in Patients with Advanced Myelodysplastic Syndromes (MDS).
Background: Early MDS becomes more advanced as immature myeloid cells proliferate, angiogenesis increases, genetic lesions… 
2006
2006
Use of Lenalidomide (Revlimid® +/− Corticosteroids in Relapsed/Refractory Multiple Myeloma Patients with Elevated Baseline Serum Creatinine Levels.
Lenalidomide (Revlimid®; Rev) is an important novel agent for the treatment of multiple myeloma (MM) patients (pts). Since MM pts… 
2006
2006
Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.
Background: Lenalidomide (Revlimid®) in combination with dexamethasone was approved in the US on June 29, 2006 for the treatment… 
2005
2005
A Phase 1 Trial of Lenalidomide (REVLIMID®) with Bortezomib (VELCADE®) in Relapsed and Refractory Multiple Myeloma.
Introduction: Bortezomib and lenalidomide are active agents in multiple myeloma (MM), and preclinical data showing additive… 
2005
2005
Results of Phase II Study of Lenalidomide (L) {Revlimid ® } in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).
Introduction: Lenalidomide (L) is a compound in a new group of drugs called ImiDs® which have Immunomodulatory properties and… 
2005
2005
Antileukemic effects of novel immunomodulatory agent lenalinomide (L) with or without rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL…
6557 Introduction: Tumor microenvironment (ME) and cytokine milieu play an important role in CLL cell survival, growth and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)